Now Available: EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

Cushing's syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action. CS is associated with increased mortality caused by complications due to excess cortisol.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate of 0.59% in the forecast period. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases.

Full Report Details at
- http://www.fastmr.com/prod/906540_epicast_report_cushings_syndrome_epidemiology.aspx?afid=301

For this analysis, GlobalData epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the age- and sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provided detailed, clinically relevant segmentations for Cushing's disease in order to improve the management of the disease.

Scope

* The Cushing's syndrome (CS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
* The CS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to Get this Report

* Develop business strategies by understanding the trends shaping and driving the global CS market.
* Quantify patient populations in the global CS market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CS therapeutics in each of the markets covered.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023
- EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023
- EpiCast Report: Dengue - Epidemiology Forecast to 2023
- EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
- EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023